Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke(Harvard University), Pasi A. Jänne(Harvard University), Marzia Capelletti(Caris Life Sciences (United States)), Luca Toschi(IRCCS Humanitas Research Hospital), Eugene Lifshits(Massachusetts General Hospital), Neal I. Lindeman(Cornell University), Kreshnik Zejnullahu(Beth Israel Deaconess Medical Center), Jeffrey A. Engelman(Cancer Research Center), Carly Murphy(Brigham and Women's Hospital), Sara Akhavanfard(Massachusetts General Hospital), A. John Iafrate(Massachusetts General Hospital), Tony Mok(Chinese University of Hong Kong), Andrew M. Rogers(Beth Israel Deaconess Medical Center), James G. Christensen, Lecia V. Sequist(Harvard University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Charles Lee(Jackson Laboratory), Yun Xiao(Brigham and Women's Hospital), Dora Dias‐Santagata(Harvard University), Beow Y. Yeap(Harvard University), Youngchul Song(Beth Israel Deaconess Medical Center)
Cited by 1,062
Related Papers
A global reference for human genetic variation
|Nature|2015|19.9k
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k